Article

Current State of Art Therapy for MPM and Future Options Focus on Immunotherapy

2023-11-17

Abstract excerpt

Malignant pleural mesothelioma (MPM) is a locally aggressive disease related to asbestos exposure with a median survival for untreated patients of 4-8 months. The combination of chemotherapy based in platinum and antifolate is the standard treatment and the addition of bevacizumab adds two months of gain in median survival. Recently in first-line treatment, immunotherapy combining nivolumab with ipilimumab has bee...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f005818b-242b-583e-80e2-985ce42fa036
DOI: 10.20944/preprints202311.1174.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Current State of Art Therapy for MPM and Future Options Focus on ImmunotherapyDOI 10.20944/preprints202311.1174.v1Read

Progress and challenges in Mesothelioma: From bench to bedside.Semantic proximity Read

Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this diseaseSemantic proximity Read

[Malignant pleural mesothelioma: 2013 state of the art].Semantic proximity Read

Multimodality treatment of malignant pleural mesotheliomaSemantic proximity Read

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaSemantic proximity Read

Immune Microenvironment and Genetics in Malignant Pleural MesotheliomaSemantic proximity Read

Genomics and Functional Genomics of Malignant Pleural MesotheliomaSemantic proximity Read

Towards a Better Understanding of Mesothelioma: A Comprehensive Review of Diagnosis, Therapy and BiomarkersSemantic proximity Read

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesotheliomaSemantic proximity Read

Molecular analyses of malignant pleural mesotheliomaSemantic proximity Read

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity Read

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.Semantic proximity Read